Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Jan 4, 2023
Date Accepted: Sep 14, 2023

The final, peer-reviewed published version of this preprint can be found here:

Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study

Marks VA, Hsiang WR, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Pantel H, Berger ER, Boffa DJ, Cavallo JA, Leapman MS

Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study

JMIR Cancer 2023;9:e45518

DOI: 10.2196/45518

PMID: 37917149

PMCID: 10654905

Telehealth Availability for Cancer Care during the COVID-19 Pandemic: A Cross-Sectional Study

  • Victoria A Marks; 
  • Walter R Hsiang; 
  • James Nie; 
  • Waez Umer; 
  • Afash Haleem; 
  • Bayan Galal; 
  • Irene Pak; 
  • Dana Kim; 
  • Michelle C Salazar; 
  • Haddon Pantel; 
  • Elizabeth R Berger; 
  • Daniel J Boffa; 
  • Jaime A Cavallo; 
  • Michael S Leapman

ABSTRACT

Background:

Telehealth was an important method for maintaining continuity of cancer care during the coronavirus pandemic, however it is unknown whether services were equally available across cancer hospitals.

Objective:

To assess telehealth availability at cancer hospitals for new and established patients with common cancers.

Methods:

We conducted a national cross-sectional secret shopper study to assess telehealth availability at cancer hospitals from June-November 2020 for new and established patients with colorectal, breast, and skin (melanoma) cancer. We examined facility-level factors to determine predictors of telehealth availability.

Results:

Of the 312 investigated facilities, 96% provided telehealth services for at least one cancer site. Telehealth was less available to new compared to established patients (72% versus 96%). The surveyed cancer hospitals offered the most telehealth visits for breast cancer (85% of hospitals) while offering the least amount for melanoma patients (74%). A majority of hospitals offered telehealth for all three cancer types (52%). Telehealth availability was weakly correlated across cancer types within a given facility for new (r=0.16, 95% CI: 0.09-0.23) and established (r = 0.14, 95% CI: 0.08-0.21) patients. Telehealth was more commonly available for new patients at facilities that were NCI designated, medical school affiliated, major teaching sites, with high total admissions, and with below average timeliness of care. Telehealth availability for established patients was highest at Academic Comprehensive Cancer Programs, nongovernment, nonprofit facilities, medical school affiliated facilities, accountable care organizations, and facilities with high total admissions.

Conclusions:

Despite an increase in telehealth services for patients with cancer during the COVID-19 pandemic, we identified differences in access across cancer hospitals.


 Citation

Please cite as:

Marks VA, Hsiang WR, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Salazar MC, Pantel H, Berger ER, Boffa DJ, Cavallo JA, Leapman MS

Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study

JMIR Cancer 2023;9:e45518

DOI: 10.2196/45518

PMID: 37917149

PMCID: 10654905

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.